My Watchlist
Indicators
REW 40 Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by BeOne Medicines Ltd.

BeOne Medicines’ Sonrotoclax Granted Breakthrough Therapy Designation by U.S. FDA
From BeOne Medicines Ltd.
Via Business Wire
Tickers ONC
BeOne Medicines Announces Positive Topline Results for Sonrotoclax in Relapsed or Refractory Mantle Cell Lymphoma (MCL)
From BeOne Medicines Ltd.
Via Business Wire
Tickers ONC
European Commission Approves TEVIMBRA® as Neoadjuvant/Adjuvant NSCLC Treatment Ahead of Late-Breaking Data Presentation at WCLC 2025
From BeOne Medicines Ltd.
Via Business Wire
Tickers ONC
BeOne to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference
From BeOne Medicines Ltd.
Via Business Wire
Tickers ONC
BeOne Medicines Announces IMDELLTRA Royalty Purchase Agreement for up to $950 Million
From BeOne Medicines Ltd.
Via Business Wire
Tickers ONC
European Commission Approves Tablet Formulation of BeOne Medicines’ BRUKINSA® for All Approved Indications
From BeOne Medicines Ltd.
Via Business Wire
Tickers ONC
BeOne Medicines Announces Second Quarter 2025 Financial Results and Business Updates
From BeOne Medicines Ltd.
Via Business Wire
Tickers ONC
BeOne Medicines Receives PRIME Designation from the European Medicines Agency for BGB-16673 in Waldenstrom’s Macroglobulinemia
From BeOne Medicines Ltd.
Via Business Wire
Tickers ONC
BeOne Medicines Receives Positive CHMP Opinion for TEVIMBRA® in Neoadjuvant/Adjuvant NSCLC Treatment
From BeOne Medicines Ltd.
Via Business Wire
Tickers ONC
BeOne Medicines to Announce Second Quarter 2025 Financial Results on August 6
From BeOne Medicines Ltd.
Via Business Wire
Tickers ONC
European Commission Approves TEVIMBRA® in Combination with Chemotherapy as a First-Line Treatment for Nasopharyngeal Carcinoma
From BeOne Medicines Ltd.
Via Business Wire
Tickers ONC
BeOne Medicines Showcases Groundbreaking Oncology Pipeline at R&D Day
From BeOne Medicines Ltd.
Via Business Wire
Tickers ONC
BeOne Medicines Receives Positive CHMP Opinion for Tablet Formulation of BRUKINSA®
From BeOne Medicines Ltd.
Via Business Wire
Tickers ONC
BeOne Medicines Showcases Breakthrough Data in CLL and MCL at EHA 2025
From BeOne Medicines Ltd.
Via Business Wire
Tickers ONC
U.S. FDA Approves Tablet Formulation of BeOne’s BRUKINSA® for All Approved Indications
From BeOne Medicines Ltd.
Via Business Wire
Tickers ONC
BeOne Medicines to Host Investor R&D Day Webcast on June 26, 2025
From BeOne Medicines Ltd.
Via Business Wire
Tickers ONC
BeOne Medicines Unveils Promising Clinical Data for Two Novel Breast Cancer Therapies at ASCO 2025
From BeOne Medicines Ltd.
Via Business Wire
Tickers ONC
BeOne Medicines Presents New SEQUOIA Study Results Reinforcing BRUKINSA’s Differentiated Profile with or without Venetoclax in Frontline CLL at ASCO 2025
From BeOne Medicines Ltd.
Via Business Wire
Tickers ONC
BeOne Medicines Launches Following Redomiciliation to Switzerland, Marking a New Chapter in Global Oncology
From BeOne Medicines Ltd.
Via Business Wire
Tickers ONC
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.